» Articles » PMID: 15101560

Biochemical Analysis of Neutral Endopeptidase Activity Reveals Independent Catabolism of Atrial and Brain Natriuretic Peptide

Overview
Journal Biol Chem
Specialty Biochemistry
Date 2004 Apr 23
PMID 15101560
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Recent reports presented contradictory results regarding the catabolism of mature atrial (ANP) and brain (BNP) natriuretic peptides in circulation. Especially the role of neutral endopeptidase (NEP) in BNP degradation was conversely discussed. Our present in vitro-studies characterize the NEP-dependent metabolism of ANP and BNP in different tissues via HPLC-analysis using NEP-deficient mice and specific NEP inhibitors. Our results show a strong tissue-dependent degradation pattern of both peptides, which are not only due to the different NEP activities in these tissues. Whereas NEP rapidly degraded ANP, it had no influence in BNP-metabolism. Additional experiments with purified NEP confirmed this result. Moreover, we describe a degradation of ANP and BNP in NEP-deficient- and NEP-inhibited membranes. Consequently, we postulate the existence of at least one further natriuretic peptide (NP) degrading enzyme, which has not been characterized yet. Thus, the commonly accepted model of the natriuretic peptide system with NEP as the central degrading peptidase has to be partly revised. Moreover, the NEP-independent BNP degradation provides an effective means for achieving a beneficial BNP increase in cardiovascular pathology by inhibiting the assumed novel NP-degrading peptidase(s).

Citing Articles

The virtually mature B-type natriuretic peptide (BNP1-32) is a precursor for the more effective BNP1-30.

Schwiebs A, Wang Y, Moore A, Zhu X, Pankow K, Siems W Br J Pharmacol. 2019; 177(6):1424-1433.

PMID: 31691951 PMC: 7056463. DOI: 10.1111/bph.14890.


B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Myhre P, Vaduganathan M, Claggett B, Packer M, Desai A, Rouleau J J Am Coll Cardiol. 2019; 73(11):1264-1272.

PMID: 30846338 PMC: 7955687. DOI: 10.1016/j.jacc.2019.01.018.


Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.

Chen Y, Burnett Jr J Clin Chem. 2017; 63(1):108-115.

PMID: 28062615 PMC: 6613397. DOI: 10.1373/clinchem.2016.262907.


Analytical Issues with Natriuretic Peptides - has this been Overly Simplified?.

Semenov A, Katrukha A EJIFCC. 2016; 27(3):189-207.

PMID: 27683533 PMC: 5009944.


New function for an old enzyme: NEP deficient mice develop late-onset obesity.

Becker M, Siems W, Kluge R, Gembardt F, Schultheiss H, Schirner M PLoS One. 2010; 5(9).

PMID: 20862277 PMC: 2940827. DOI: 10.1371/journal.pone.0012793.